Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 6/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.55 |
| ▸ | NTRK3 | Q16288 | 5/20 | 0.55 |
| ▸ | NTRK2 | Q16620 | 5/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202289 | 0.91 | NTRK1 (0.53) | FYNNTRK1NTRK3NTRK2CNR2 | |
| SCHEMBL1202642 | 0.90 | PIM1 (0.56) | FYNNTRK1NTRK3NTRK2PIM1 | |
| SCHEMBL1202338 | 0.89 | FYN (0.66) | FYNNTRK1NTRK3NTRK2PIM1 | |
| SCHEMBL1202730 | 0.87 | NTRK1 (0.55) | FYNNTRK1NTRK3NTRK2PIM1 | |
| SCHEMBL1203403 | 0.86 | NTRK1 (0.50) | FYNNTRK1NTRK3NTRK2PIM1 | |
| SCHEMBL1202933 | 0.84 | NTRK1 (0.51) | FYNNTRK1PIM1KDM4EALDH1A1 | |
| SCHEMBL1203100 | 0.84 | PIM1 (0.66) | FYNNTRK1NTRK3NTRK2PIM1 | |
| SCHEMBL1203131 | 0.83 | FYN (0.53) | FYNNTRK1NTRK3NTRK2PIM1 | |
| SCHEMBL1203780 | 0.83 | FYN (0.53) | FYNNTRK1NTRK3NTRK2PIM1 | |
| SCHEMBL1203286 | 0.82 | FYN (0.53) | FYNNTRK1NTRK3NTRK2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | FYN 403/4885NTRK1 755/4885NTRK3 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.